AEGiS-15IAC: Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow-up.

15th International AIDS Conference

Bangkok, Thailand - July 11-16, 2004

Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow-up.

Int Conf AIDS 2004 Jul 11-16; 15:(abstract no. MoOrB1060)

Serra MS, Oyafuso LK, Troppe BM
Hospital de Infectologia Emilio Ribas, Sao Paulo, Brazil

BACKGROUND: Lipodistrophy has become a big challenge in HIV/AIDS treatment. Facial atrophy is an unaesthetic condition related with lipodystrophy and compromises patients self-esteem and quality of life, urging for an efficient treatment.

METHODS: Patients were treated with a 30% PMMA solution, containing methylcellulose and lidocaine. Treatment consisted of parallel retro-injections in the subcutaneous areas of atrophic parts of the face. Patients were photographed before the treatment and had to come after 30 days for evaluation and a complimentary treatment, if necessary, and followed then every 6 months.

RESULTS: 504 patients were included in this study, with a minimum follow-up of one month and maximum of 5 years. PMMA injections demonstrated to be safe, lasting and with excellent aesthetic results. No unexpected side effects were observed. There was no change in viral load or CD4 count that could be related. Patients demonstrated to be satisfied with the procedure and referred improvement in their quality of life. Conclusion Facial atrophy treatment with PMMA injections demonstrated to be efficient, long lasting and safe. The treatment had a positive influence on patients, improving their quality of life and helping recover self-esteem.

Keywords: AEGIS, Polymethyl Methacrylate, Connective Tissue Diseases, Lipodystrophy, Acquired Immunodeficiency Syndrome, Viral Load, Bone Cements, Face, HIV Protease Inhibitors, HIV Infections, HIV-1, Atrophy, Anti-HIV Agents, Time, Antiretroviral Therapy, Highly Active, HIV, Humans, therapy, organization & administration, methods, drug therapy

040711
MoOrB1060